HealthSquare.com

Your Prescription Drug Destination
See all our sites for your special health needs at www.HealthCentral.com

Rosacea and Rhinophyma


Rosacea and Rhinophyma

Rosacea is a chronic skin disorder that produces flushing and dilation of the small blood vessels in the face. Tiny pimples also appear. As the disease progresses, small, thin, red lines (telangiectasia) may appear on the skin's surface. In advanced cases -- and usually only in men -- the nose becomes bulbous and red, the cheeks become puffy, and thick bumps develop on the lower half of the nose and adjacent cheek areas. We don't know what causes this condition, which is called rhinophyma, but the problem may be aggravated by stress, infection, vitamin deficiencies, and glandular upset.

To relieve rosacea, doctors often prescribe a topical antibiotic, such as metronidazole (Metrogel), which is applied directly to the affected skin. For people with more severe cases, treatment may include an oral antibiotic, such as tetracycline, minocycline, erythromycin, or doxycycline. The dilated blood vessels of telangiectasias can be closed off with a small needle, a laser, or surgery.

Rhinophyma is usually treated with surgery or dermabrasion. Most people with this disorder are advised to avoid alcohol, spicy foods, hot drinks, and smoking, and to stop using facial products that contain alcohol or other irritants.


 

Goto:








HONcode logo
We comply with the HONcode standard for health trust worthy information: verify here.
More info from:

HealthCentral.com's
Skin Cancer Site


Most Viewed
Top Skin Cancer Drugs

Latest News

  • Study looks at beachgoer's skin cancer risk
  • Vitamins C and E fail in cancer prevention study
  • Health Tip: Risk Factors for Skin Cancer
  • Vitamins C, E do not cut heart attack, stroke risk: study
  • Kid vaccines okay for kids at risk for allergies
  • Learn More

    Skin Cancer Related Drugs


    Poll
    Which of these drugs are you taking?


    More info from

    HealthCentral.com's
    Skin Cancer Site




    View all conditions
    PR Newswire
    advertisement